References
- Kantarjian H M, Dixon D, Keating M J, Talpaz M, Walters R S, McCredie K B, Freireich E J. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441–1446
- Denburg J A, Browman G. Prognostic implications of basophil differentiation in chronic myeloid leukemia. Am J Hematol 1988; 27: 110–114
- Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858
- Druker B J, Talpaz M, Resta D J. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037
- Weisberg E, Griffin J D. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 2003; 6: 231–238
- Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003; 40: 62–68
- Baccarani M, Saglio G, Goldman J, et al. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820
- Thiele J, Kvasnicka H M, Fischer R. Bone marrow histopathology in chronic myelogenous leukemia (CML) – evaluation of distinctive features with clinical impact. Histol Histopathol 1999; 14: 1241–1256
- Kvasnicka H M, Thiele J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol 2004; 19: 1245–1260
- Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas O A, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002; 99: 381–383
- Agis H, Krauth M T, Mosberger I, Müllauer L, Simonitsch-Klupp I, Schwartz L B, et al. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol 2006; 59: 396–402
- Agis H, Krauth M T, Böhm A, Mosberger I, Müllauer L, Simonitsch-Klupp I, et al. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol 2006; 125: 273–281
- Samorapoompichit P, Kiener H P, Schernthaner G H, Jordan J H, Agis H, Wimazal F, et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001; 98: 2580–2583
- Bühring H J, Simmons P J, Pudney M, Muller R, Jarrossay D, van Agthoven A, et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999; 94: 2343–2356
- Agis H, Sperr W, Herndlhofer S, Semper H, Pirc-Danoewinata H, Haas O, et al. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol 2007; 18: 1834–1841